Not investment advice. Origin reports data from public SEC filings with cryptographic provenance. No buy/sell/hold recommendations. Past performance does not indicate future results.
## LHX Falls Another 7% to $263 as Cumulative Drawdown Reaches 15% From June High
Since the July 19 observation logged LHX at $282.01, the stock has continued its slide to $262.96 as of August 26 — an additional 7% decline that brings the cumulative drawdown to approximately 15% from the $310.45 price recorded in the June 18 observation. The $23B revenue guidance remains intact across all three captured transcripts, which makes the persistent selling pressure analytically interesting: this is not a guidance-cut story, at least not yet. At $262.96 against a $67B market cap, the market appears to be discounting execution probability rather than the target itself. The gap between a stable $23B guide and a falling stock price is a signal worth tracking carefully. The filing signal structure continues to warrant attention. Risk factor matches remain elevated across three apparent filing sections (112, 15, and 8), and the 6 margin pressure flags paired with 6 risk concentration signals suggest the 10-K's internal language has not softened. With AI query volume on Origin surging from 184 to 478 all-time — a 160% increase since the June 9 data refresh — institutional interest in the filing architecture is clearly accelerating, even as price deteriorates. Watch for: a Q2 2026 earnings transcript capture that could finally expand the current three-transcript base and sharpen signal resolution; any revision to the $23B–$23.x billion revenue range, which would be the first material guidance shift; and whether the $3B discrete guidance line (free cash flow or contract-specific) holds as program mix evolves through H2.
## LHX Stabilizes Near $286 After 9% Drawdown as $23B Guidance Remains Intact but Execution Premium Compressed
The July 19 observation flagged a drop from $310.45 to $282.01; as of August 5, LHX has partially recovered to $286.12, suggesting the initial repricing has largely run its course without a fundamental guidance revision triggering it. The $23B full-year revenue target, the $11.5B segment anchor, and the $3B discrete line all remain verbatim in captured transcripts — meaning the market sold the execution premium, not the outlook itself. At $286, LHX trades roughly 8% below the June 18 level while the underlying thesis is structurally unchanged. The signal architecture from the 10-K continues to warrant scrutiny. The 112 risk factor matches remain the dominant filing signal, outpacing the 96 strategic event matches by a meaningful margin — an asymmetry that historically correlates with programs in transition rather than programs in steady-state delivery. The 6 margin pressure flags alongside 6 risk concentration signals are particularly relevant given LHX's mix shift dynamics: any degradation in fixed-price program execution could compress margins faster than the top-line holds. The AI query count has more than doubled since June 9 (184 to 407), indicating elevated investor and analyst attention to this name. Watch for: Q2 2026 earnings transcript capture — the transcript count remaining at 3 is the single largest gap in signal resolution. A fourth transcript would likely either confirm margin pressure is contained or crystallize the risk that the 10-K's density is foreshadowing. Also monitor whether the $3B guidance line gets further specified as FCF, buyback, or contract award language.
## LHX Slides Another 3% to $277 as Execution Premium Continues Eroding Despite Unchanged $23B Guidance
The decline logged in the July 19 observation ($282.01) has continued, with LHX now trading at $277.06 as of July 31 — a cumulative drop of approximately 11% from the $310.45 price recorded at the June 18 observation. Market cap remains nominally near $67B, but the sustained compression is notable precisely because the fundamental guidance anchors have not shifted: transcripts continue to reflect the $23B full-year revenue target, the ~$11.5B segment figure, and the $3B discrete line. The market is not repricing the numbers — it is repricing confidence in delivery against them. What makes this analytically significant is the divergence between signal stability and price behavior. The 10-K signal distribution remains unchanged (112 risk factor matches dominating, 6 margin pressure flags, 9 growth inflection matches), yet AI query volume on Origin has surged from 184 at the June 9 data refresh to 382 all-time — more than doubling in roughly seven weeks. That query acceleration suggests institutional or analytical attention is intensifying even as price drifts lower, which could indicate due diligence ahead of a catalyst rather than passive monitoring. Watch for: Q2 2026 earnings release, which should either validate or stress-test the $23B guide with actual segment-level revenue and margin data. The transcript count remains stuck at 3, so a new capture would materially improve signal resolution. Any revision to the $3B guidance line — whether reaffirmed as free cash flow or tied to a specific contract — warrants immediate attention given the current execution risk premium the market appears to be pricing.
## LHX Recovers to $305 as Execution Narrative Stabilizes, But 10-K Risk Density Remains the Unresolved Variable
The 9% drawdown flagged in the July 19 observation — from $310.45 to $282.01 — has partially reversed, with LHX trading at $305.20 as of July 28. The recovery erases roughly two-thirds of that decline without a corresponding change in the underlying signal structure: guidance language remains locked at $23 billion full-year revenue, the $11.5 billion segment anchor, and the $3 billion discrete line. The market appears to have treated the dip as a valuation reset rather than a thesis break, which is consistent with a stock that was pricing in steady execution at $310 and found a floor once the premium compressed modestly. What hasn't resolved is the filing signal imbalance that has persisted across all three observations. Risk factor matches (112, 15, 8 across filing sections) continue to outnumber growth inflection signals (9) by a wide margin, and the 6 margin pressure flags remain unaddressed by any transcript capture. With only 3 transcripts in the system — unchanged since June 9 — signal resolution is still limited. The AI query count has jumped from 184 to 321 all-time, suggesting elevated external interest in LHX, but that activity hasn't yet produced additional transcript data to test whether margin pressure language is intensifying as program mix evolves. Watch for: Q2 2026 earnings transcript capture, which should clarify whether the $3 billion guidance line is free cash flow or contract-specific, and whether fixed-price program exposure is contributing to the margin pressure flags embedded in the 10-K.
## LHX Drops 9% From Prior Observation as $23B Guidance Holds But Market Reprices Execution Risk
Since the June 18 observation logged LHX at $310.45, the stock has declined to $282.01 as of July 17 — a roughly 9% drawdown against a flat-to-rising defense sector backdrop. Market cap holds near $67 billion, but the price action suggests investors are reassessing the premium embedded in the $23B revenue target rather than abandoning the thesis entirely. Notably, the guidance itself appears unchanged: transcripts still reflect the $23B full-year range, the $11.5B segment anchor, and the $3B discrete line — whether free cash flow, a contract award, or capital return remains unresolved. The fact that guidance hasn't moved while the stock has is the central analytical tension here. AI query volume has accelerated meaningfully, from 184 all-time on June 9 to 287 today — a 56% increase in roughly five weeks — suggesting elevated institutional research interest coinciding with the price decline. The 10-K signal distribution is unchanged, with risk factor matches still dominating at 112 across the primary filing section, and margin pressure (6 matches) and risk concentration (6 matches) flags remaining structurally embedded. The 9 growth inflection matches continue to argue for a transformation narrative, but the market appears to be weighting the risk density more heavily at current prices. Watch for: Q2 2026 earnings — transcript count remains at just 3, severely limiting signal resolution, and a fourth capture could materially shift the margin pressure read. Clarification on the $3B guidance line and any commentary on fixed-price versus cost-plus program mix will be the key earnings variables.
## L3Harris Reaffirms $23B Revenue Target as Filing Signals Flag Elevated Risk Density
Building on the initial data refresh logged June 9, this observation incorporates three captured earnings transcripts and a fuller read of the 10-K signal distribution. The revenue guidance picture has sharpened: LHX is guiding to approximately $23 billion in full-year revenue, with a segment (likely Integrated Mission Systems or Space & Airborne) anchored near $11.5 billion, and a discrete program or capital allocation item flagged at $3 billion. At a $67 billion market cap and $310.45 per share, the stock is pricing in steady execution against that $23B target — leaving limited margin for slippage. What stands out analytically is the signal density in the 10-K. Risk factor matches dominate at 112, 15, and 8 across what appear to be three distinct filing sections, while strategic event matches (96 and 10) and risk concentration flags (6) suggest the filing is simultaneously describing an ambitious transformation and cataloguing the friction around it. The 9 growth inflection matches are notable — this is not a flat-maintenance narrative — but 6 margin pressure flags alongside risk concentration language warrants close reading, particularly given LHX's ongoing portfolio divestitures and integration costs from the 2019 L3/Harris merger tail. Watch for: Q2 2026 earnings transcript capture (transcript count sits at just 3, limiting signal resolution), any update to the $3B guidance line which may relate to free cash flow or a specific contract award, and whether margin pressure signals intensify as program mix shifts toward cost-plus versus fixed-price work.